Feiran Chen, Jun Du, Xu-sheng Chen, Qing Yang, Lei Diao, Xin Yao
{"title":"短期膀胱内注射吉西他滨与长期膀胱内注射表柔比星治疗中高风险非肌层浸润性膀胱癌的有效性和安全性:一项试点研究","authors":"Feiran Chen, Jun Du, Xu-sheng Chen, Qing Yang, Lei Diao, Xin Yao","doi":"10.1007/s44178-024-00076-x","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"509 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of short-term intravesical gemcitabine vs. long-term intravesical epirubicin in the treatment of moderate to high-risk non-muscle-invasive bladder cancer: a pilot study\",\"authors\":\"Feiran Chen, Jun Du, Xu-sheng Chen, Qing Yang, Lei Diao, Xin Yao\",\"doi\":\"10.1007/s44178-024-00076-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73245,\"journal\":{\"name\":\"Holistic integrative oncology\",\"volume\":\"509 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Holistic integrative oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s44178-024-00076-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Holistic integrative oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s44178-024-00076-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Efficacy and safety of short-term intravesical gemcitabine vs. long-term intravesical epirubicin in the treatment of moderate to high-risk non-muscle-invasive bladder cancer: a pilot study